

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Algernon Pharmaceuticals Inc. (the “**Issuer**” or the “**Company**”).

Trading Symbol: AGN

Number of Outstanding Listed Securities: 21,640,762

Date: April 4, 2024

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

During March 2024 the Company finalized an agreement with Seyltx, Inc. (“Seyltx”), a privately owned U.S. based drug development company, for the acquisition of the Company’s Ifenprodil idiopathic pulmonary fibrosis (“IPF”) / chronic cough research program for the purchase price of \$2.7 million (USD \$2.0 million) cash and a 20% common share equity position in Seyltx. The Company had previously announced on November 22, 2023 that it had signed a Letter of Intent (“LOI”) with Seyltx, to acquire the research program. Seyltx plans to initiate an Ifenprodil multi-center Phase 2b placebo-controlled chronic cough study in Calendar 2024. Algernon’s clinical management team will be available to provide support, oversight, and management of the study.

With the completion of the transaction with Seyltx, the Company’s main activity has shifted to advancing its N,N-dimethyltryptamine (“DMT”) stroke research program as well as its chronic kidney disease (“CKD”) research program with Repirinast.

The Company continues to plan the advancement of a phase 2 clinical trial for DMT in stroke.

2. Provide a general overview and discussion of the activities of management.

During March 2024 the Company finalized an agreement with Seyltx for the acquisition of the Company’s Ifenprodil research program for the purchase price of \$2.7 million (USD \$2.0 million) cash and a 20% common share equity position in Seyltx.

With the completion of the transaction with Seyltx, the Company’s main activity has shifted to advancing its DMT stroke research program as well as its CKD research program with Repirinast.

The Company continues to plan the advancement of a phase 2 clinical trial for DMT in stroke.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the dispositions was to a Related Person of the Issuer and provide details of the relationship.

During March 2024 the Company finalized an agreement with Seyltx, a privately owned U.S. based drug development company, for the acquisition of the Company's Ifenprodil IPF/chronic cough research program for the purchase price of \$2.7 million (USD \$2.0 million) cash and a 20% common share equity position in Seyltx, with a nominal deemed value. The Company had previously announced on November 22, 2023 that it had signed an LOI with Seyltx, to acquire the research program. Seyltx plans to initiate an Ifenprodil multi-center Phase 2b placebo-controlled chronic cough study in Calendar 2024. Algernon's clinical management team will be available to provide support, oversight, and management of the study.

Seyltx is an arms-length entity to the Company and the sale price was determined through arm's length negotiations between the Company and Seyltx.

The Company paid Maxim Group LLC ("Maxim") a cash fee in connection with the transaction and will issue 200,000 of the Company's common shares to Maxim

under an Advisory Agreement signed by the Company and previously announced on June 27, 2023.

7. Describe the acquisition of new customers or loss of customers.

None.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

9. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None.

10. Report on any labour disputes and resolutions of those disputes if applicable.

None.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

13. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
N/A	N/A	N/A	N/A

14. Provide details of any loans to or by Related Persons.

None.

15. Provide details of any changes in directors, officers or committee members.

None.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None

The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. Please to the "Risks Related To The Business" section of the Issuer's management discussion and analysis for the year ended August 31, 2023, which is available on SEDAR at www.sedar.com.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 4, 2024

James Kinley
Name of Director or Senior
Officer

"James Kinley"
Signature

CFO
Official Capacity

<i>Issuer Details</i> Name of Issuer	For Month End	Date of Report YY/MM/DD
Algernon Pharmaceuticals Inc.	March 31, 2024	2024/04/04
Issuer Address Suite 400 – 601 West Broadway Street		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V5Z 4C2	NA	(604) 398-4175 ext. 701
Contact Name	Contact Position	Contact Telephone No.
James Kinley	CFO	(604) 398-4175 ext. 701